|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for PAX5(NM_016734.2) Search again
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
Summary
This gene encodes a member of the paired box (PAX) family of transcription factors. The central feature of this gene family is a novel, highly conserved DNA-binding motif, known as the paired box. PAX proteins are important regulators in early development, and alterations in the expression of their genes are thought to contribute to neoplastic transformation. This gene encodes the B-cell lineage specific activator protein that is expressed at early, but not late stages of B-cell differentiation. Its expression has also been detected in developing CNS and testis and so the encoded protein may also play a role in neural development and spermatogenesis. This gene is located at 9p13, which is involved in t(9;14)(p13;q32) translocations recurring in small lymphocytic lymphomas of the plasmacytoid subtype, and in derived large-cell lymphomas. This translocation brings the potent E-mu enhancer of the IgH gene into close proximity of the PAX5 promoter, suggesting that the deregulation of transcription of this gene contributes to the pathogenesis of these lymphomas. Alternatively spliced transcript variants encoding different isoforms have been described but their biological validity has not been determined.
Gene References into function
- interaction with Daxx resulting in transcriptional activation in B cells
- were expressed by human PCs following a gradient of increasing maturity in the direction: tonsil-->blood-->BM
- Multiple isoforms of Pax5 & low levels of the full-length Pax5 were seen in B cells from MM patients. Premature Blimp-1 expression & altered, deficient Pax5 expression causes some proliferating B cells to prematurely differentiate to plasma cells.
- The frequent expression of B-cell-specific activator protein (BSAP)in Reed-Sternberg (H/RS) cells of classical Hodgkin's disease provides further evidence for its B-cell origin and helps to identify H/RS cells.
- Retrovirally expressed human Pax-5 protein activates endogenous early B-cell-specific mb-1 genes in mouse plasmacytoma cells, but only when the promoter is hypomethylated.
- Pax-5 is a key regulator of the B-cell-restricted expression of the CD23a isoform.
- Isoform expression is modulated by specific signaling pathways in B lymphocytes.
- Results indicate that PAX5 is a more specific marker than CD79a for B-cell ALL diagnosis.
- Expression of mRNA for a newly identified Pax5 exon is reduced in multiple myeloma
- In both Richter's transformation and prolymphocytic transformation, high-levels of AID mRNA expression and high-frequency mutations of Pax-5 protein genes were detected.
- These findings indicate a direct activating function for Pax5 in RAG-mediated immunoglobulin V(H)-to-DJ(H) recombination.
- Results confirm that Pax-5 is expressed regularly in poorly differentiated neuroendocrine tumors.
- Pax5 maintains cellular identity by repressing gene expression throughout B cell differentiation [review]
- BSAP can probably contribute to T-cell lymphomagenesis not only in vitro, but also in vivo. It is rarely expressed in peripheral T-cell lymphoma, thus its detection on lymphoid malignancies cannot be considered definitively lineage specific.
- PAX5 mutation is associated with splenic and nodal marginal zone B-cell lymphomas
- PAX5 is a useful immunohistologic marker for the interrogation of undifferentiated neoplasms. It is an extremely specific marker of the B lineage.
- PAX5 was identified as a useful tumor marker for the diagnosis of pediatric large cell lymphoma.
- EBV ensures the B-cell specificity of its growth-transforming function by exploiting BSAP/Pax5 as a lineage-specific activator of the transforming program.
- Simultaneous nuclear expression of the transcription factor gene PAX5 suggested that this major driver of B-cell differentiation did not preclude expression of CD3epsilon
- Repression of PRDM1 by BSAP reveals an autoregulatory negative-feedback loop that could play a relevant role in controlling human PC differentiation.
- stimulation of neoplastic growth by Pax5 occurs through B cell receptor and is sensitive to genetic and pharmacological inhibitors of this pathway
- that transcription factors Xbp-1, Blimp-1, and PAX-5-encoded BSAP play important roles in the regulation of plasmacytic differentiation and exert their effects on differentiation induced by low 2ME2 concentrations
- PAX-5 is a useful marker for the discrimination of low- to intermediate-grade pulmonary neuroendocrine neoplasms from high-grade ones.
- Pax-5 protein expression is infrequent in bladder cancer
- Pax-5B suppression led to an increase of CD19 mRNA and cell surface protein expression.
- PAX-5 is the most sensitive and reliable immunohistochemical marker for B-cell malignancies
- I.v. injection of an anti-PAX5 CTL clone into immunodeficient mice bearing s.c. human tumors resulted in specific growth inhibition of PAX5-expressing tumors.
- deletion and mutation of the homologous PAX5 allele, providing further support for the key role of PAX5 in unbalanced translocations in cancer
- several novel PAX5 partner genes not only comprise transcription factors but also structural proteins and genes involved in signal transduction, which at least in part have not been implicated in tumorigenesis.
- PAX 5 expression was evaluated in small cell lung cancer and other cancers; determined that PAX5 could regulate the transcription of c-Met; PAX5 protein expression was relatively strong in small-cell lung cancer; expression was not detected in non-SCLC
